Advertisement
ResearchIn-Press PreviewCell biologyPulmonology Open Access | 10.1172/JCI172826
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Fortier, S. in: JCI | PubMed | Google Scholar
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Walker, N. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Penke, L. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Baas, J. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Shen, Q. in: JCI | PubMed | Google Scholar
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Speth, J. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Huang, S. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Zemans, R. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Bennett, A. in: JCI | PubMed | Google Scholar |
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2Department of Pharmacology, Yale University School of Medicine, New Haven, United States of America
Find articles by Peters-Golden, M. in: JCI | PubMed | Google Scholar |
Published March 21, 2024 - More info
Fibrosis following tissue injury is distinguished from normal repair by the accumulation of pathogenic and apoptosis-resistant myofibroblasts (MFs), which arise primarily by differentiation from resident fibroblasts. Endogenous molecular brakes that promote MF dedifferentiation and clearance during spontaneous resolution of experimental lung fibrosis may provide insights that could inform and improve treatment of progressive pulmonary fibrosis in patients. Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP1) influences cellular phenotype and fate through precise and timely regulation of MAPK activity within various cell types and tissues, yet its role in lung fibroblasts and pulmonary fibrosis has not been explored. Utilizing gain- and loss-of-function studies, we found that MKP1 promoted lung MF dedifferentiation and restored their sensitivity to apoptosis — effects determined to be mainly dependent upon its dephosphorylation of p38α MAPK (p38α). Fibroblast-specific deletion of MKP1 following peak bleomycin-induced lung fibrosis largely abrogated its subsequent spontaneous resolution. Such resolution was restored by treating these transgenic mice with the p38α inhibitor VX-702. We conclude that MKP1 is a critical antifibrotic brake whose inhibition of pathogenic p38α in lung fibroblasts is necessary for fibrosis resolution following lung injury.